bpc 157 windermere Peptide Therapy — Exclusive Med Aesthetics BPC-157 | Research Grade Peptide

Oral dosing ranges discussed in research community use Phase Weeks 12 (start low) Daily dose 50 mg once daily Notes Morning dosing is the pattern most often reported

For plantar fasciitis, subcutaneous injection near the affected area is the preferred route

Cytoprotective gastric pentadecapeptide BPC 157 resolves major vessel occlusion disturbances

BPC-157 has a molecular weight of approximately 1,419 Da on the larger end for nasal mucosal absorption which may constrain bioavailability compared to smaller peptides like Semax (which weighs 604 Da and is specifically designed for nasal delivery).8 Who nasal delivery may be relevant for (research context): Neurological or brain-adjacent applications Patients for whom injection is contraindicated Situations requiring rapid onset with non-invasive administration Research protocols studying nose-to-brain peptide pathways What to be realistic about: No peer-reviewed human trials on intranasal BPC-157 exist as of 2026 Nasal absorption of BPC-157 is less predictable than for smaller peptides Dosing standardisation for nasal BPC-157 is not established Consult a licensed provider before considering this route Peptide Delivery Method Comparison Table How to Choose the Right BPC-157 Delivery Method for Your Goal Matching the delivery method to the clinical goal is the single most important decision in BPC-157 therapy

The critical advantage of B12 injections over oral supplements lies in their absorption and immediate availability to the body